314 related articles for article (PubMed ID: 25287138)
1. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.
Conway K; Edmiston SN; May R; Kuan PF; Chu H; Bryant C; Tse CK; Swift-Scanlan T; Geradts J; Troester MA; Millikan RC
Breast Cancer Res; 2014 Oct; 16(5):450. PubMed ID: 25287138
[TBL] [Abstract][Full Text] [Related]
2. Methylation profiling with a panel of cancer related genes: association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer.
Rønneberg JA; Fleischer T; Solvang HK; Nordgard SH; Edvardsen H; Potapenko I; Nebdal D; Daviaud C; Gut I; Bukholm I; Naume B; Børresen-Dale AL; Tost J; Kristensen V
Mol Oncol; 2011 Feb; 5(1):61-76. PubMed ID: 21212030
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypes.
Park SY; Kwon HJ; Choi Y; Lee HE; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Mod Pathol; 2012 Feb; 25(2):185-96. PubMed ID: 22037257
[TBL] [Abstract][Full Text] [Related]
4. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
[TBL] [Abstract][Full Text] [Related]
5. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer.
Tommasi S; Karm DL; Wu X; Yen Y; Pfeifer GP
Breast Cancer Res; 2009; 11(1):R14. PubMed ID: 19250546
[TBL] [Abstract][Full Text] [Related]
6. Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study.
Conway K; Edmiston SN; Tse CK; Bryant C; Kuan PF; Hair BY; Parrish EA; May R; Swift-Scanlan T
Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):921-30. PubMed ID: 25809865
[TBL] [Abstract][Full Text] [Related]
7. Homeobox A11 hypermethylation indicates unfavorable prognosis in breast cancer.
Xia B; Shan M; Wang J; Zhong Z; Geng J; He X; Vu T; Zhang D; Pang D
Oncotarget; 2017 Feb; 8(6):9794-9805. PubMed ID: 28038461
[TBL] [Abstract][Full Text] [Related]
8. Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels.
Lian ZQ; Wang Q; Li WP; Zhang AQ; Wu L
Int J Oncol; 2012 Aug; 41(2):629-38. PubMed ID: 22581028
[TBL] [Abstract][Full Text] [Related]
9. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma.
Kang JH; Kim SJ; Noh DY; Park IA; Choe KJ; Yoo OJ; Kang HS
Lab Invest; 2001 Apr; 81(4):573-9. PubMed ID: 11304577
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.
Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
Breast Cancer Res; 2010; 12(6):R105. PubMed ID: 21122106
[TBL] [Abstract][Full Text] [Related]
11. An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.
Holm K; Staaf J; Lauss M; Aine M; Lindgren D; Bendahl PO; Vallon-Christersson J; Barkardottir RB; Höglund M; Borg Å; Jönsson G; Ringnér M
Breast Cancer Res; 2016 Feb; 18(1):27. PubMed ID: 26923702
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation epigenotypes in breast cancer molecular subtypes.
Bediaga NG; Acha-Sagredo A; Guerra I; Viguri A; Albaina C; Ruiz Diaz I; Rezola R; Alberdi MJ; Dopazo J; Montaner D; Renobales M; Fernández AF; Field JK; Fraga MF; Liloglou T; de Pancorbo MM
Breast Cancer Res; 2010; 12(5):R77. PubMed ID: 20920229
[TBL] [Abstract][Full Text] [Related]
13. Basal-like breast cancer displays distinct patterns of promoter methylation.
Lee JS; Fackler MJ; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Sukumar S
Cancer Biol Ther; 2010 Jun; 9(12):1017-24. PubMed ID: 20505321
[TBL] [Abstract][Full Text] [Related]
14. HOXD13 methylation status is a prognostic indicator in breast cancer.
Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation and hormone receptor status in breast cancer.
Benevolenskaya EV; Islam AB; Ahsan H; Kibriya MG; Jasmine F; Wolff B; Al-Alem U; Wiley E; Kajdacsy-Balla A; Macias V; Rauscher GH
Clin Epigenetics; 2016; 8():17. PubMed ID: 26884818
[TBL] [Abstract][Full Text] [Related]
16. Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis.
Perez-Janices N; Blanco-Luquin I; Torrea N; Liechtenstein T; Escors D; Cordoba A; Vicente-Garcia F; Jauregui I; De La Cruz S; Illarramendi JJ; Coca V; Berdasco M; Kochan G; Ibañez B; Lera JM; Guerrero-Setas D
Oncotarget; 2015 Sep; 6(27):23944-58. PubMed ID: 26284587
[TBL] [Abstract][Full Text] [Related]
17. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns.
Holm K; Hegardt C; Staaf J; Vallon-Christersson J; Jönsson G; Olsson H; Borg A; Ringnér M
Breast Cancer Res; 2010; 12(3):R36. PubMed ID: 20565864
[TBL] [Abstract][Full Text] [Related]
18. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
19. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
20. Promoter CpG island hypermethylation during breast cancer progression.
Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
